GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » 50-Day SMA

DSKYF (Daiichinkyo Co) 50-Day SMA : $31.31 (As of Dec. 13, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-12-13), Daiichinkyo Co's 50-Day SMA is $31.31. It's 20-Day SMA is $30.00 and 200-Day SMA is $34.13.


Competitive Comparison of Daiichinkyo Co's 50-Day SMA

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's 50-Day SMA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's 50-Day SMA falls into.



Daiichinkyo Co  (OTCPK:DSKYF) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSKYF) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Daiichinkyo Co 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co Business Description

Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

From GuruFocus

Daiichi Sankyo Co Ltd ASCO Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd R&D Day Transcript

By GuruFocus Research 02-13-2024

Q2 2022 Daiichi Sankyo Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd Enhertu Business Briefing Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd ESMO 2021 Highlights Call Transcript

By GuruFocus Research 02-13-2024